Articles By Wayne Koberstein, Executive Editor

Companies To Watch: Arena Pharmaceuticals
Companies To Watch: Arena Pharmaceuticals By early 2016, Arena’s board decided to remake the company, beginning with new management and a new strategy. Since then, the company has evolved back to a core drug development platform.  Continue Reading...
  • Cytokinetics: Keeping Its Sights On Independence
    Cytokinetics: Keeping Its Sights On Independence

    Can a biopharma company have a soul? If so, the soul should be one that endures. “The biology is the soul of our company,” says Robert Blum, president and CEO of Cytokinetics. “We have pioneered an area of biology — muscle activation — proven to offer a compelling pharmacology.

  • The Mechanics Of Hyperbole
    The Mechanics Of Hyperbole

    Oncology isn’t the only therapeutic area subject to the hyperbole of hope. It is just the most perfect example of hype, an all-too-common state of mind in the “cancer community.

  • Ipsen In The USA — Building & Leading The Subsidiary As Startup
    Ipsen In The USA — Building & Leading The Subsidiary As Startup

    Cynthia Schwalm, president, North American commercial operations for Ipsen, gives the backstory of what happened when this company decided to change its approach to the U.S. market.

  • Company To Watch: ProMIS Neurosciences
    Company To Watch: ProMIS Neurosciences

    ProMIS Neurosciences believes inaccurate targeting of mAbs is to blame, in fact, for lack of progress against Alzheimer’s disease.

  • Chasing Invention: Jeffrey Kindler At The Helm Of Centrexion
    Chasing Invention: Jeffrey Kindler At The Helm Of Centrexion

    As former chairman and CEO of Pfizer, Jeffrey Kindler dealt with the frustrating conundrum of ballooning R&D budgets tracking alongside plunging R&D productivity. Now as he leads this chronic pain biopharma startup, he has a whole new set of challenges.

  • The Solar Eclipse And Other Irrelevancies
    The Solar Eclipse And Other Irrelevancies

    As a trade journalist, I often face the challenge of relevancy. Is what I’m writing about really useful and germane to readers as members of a particular industry?

  • Company To Watch: GeNeuro
    Company To Watch: GeNeuro

    Outside skepticism about GeNeuro’s scientific concept has made fund-raising even harder than usual for a startup. But the Swiss company has found considerable support in Europe.

  • Astellas Puts Oncology Front & Center
    Astellas Puts Oncology Front & Center

    Astellas has placed a big emphasis on oncology this year, pointing to its many assets, particularly in targeted therapies that are later stage, but also focusing through partnerships on immuno-oncology (IO). A conversation with Drs. Steven Benner, head of oncology, and Peter Sandor, head of oncology marketing strategy, follows.

  • An Introvert’s View Of The Industry — Or Travels With Incredulity
    An Introvert’s View Of The Industry — Or Travels With Incredulity

    When I leave my writer’s lair and go out into the world, I feel like the tortoise in a race of hares. People move around me at the speed of light, most lost in their screens, smiling at machines.

  • Our Annual Cancer Immunotherapy Update
    Our Annual Cancer Immunotherapy Update

    When we started our series, “Combination Cancer Immunotherapy — A Virtual Roundtable,” in 2014, our basic assumptions were not the consensus view. We assumed immunotherapy, now more commonly called immuno-oncology (IO), would become the dominant form of cancer treatment and central target of academic and industry research in oncology. We assumed a single, backbone therapy would become the pillar around which combinations of therapeutics with complementary targets would form. And we assumed the IO field, especially in its combination approaches, would pose profound scientific and business challenges as it took over as the central focus of oncology in general. Our assumptions turned out to be correct. Now, all IO has to do is catch up with itself.

  • Companies To Watch: Frequency Therapeutics
    Companies To Watch: Frequency Therapeutics

    Frequency Therapeutics is an early-stage developer of small molecule drugs to activate “progenitor cells” and restore healthy tissue. Its lead program is in treating hearing loss by regenerating sensory cells in the inner ear, for which it is planning a Phase 1 trial to launch in mid-2018.

  • Takeda Aims To Invent It Here & There
    Takeda Aims To Invent It Here & There

    Takeda’s chief medical and scientific officer talks about R&D, business development, and partnering.

  • Companies To Watch: Noveome Biotherapeutics
    Companies To Watch: Noveome Biotherapeutics

    To heal the wounds — maintaining and restoring cellular homeostasis with novel secretomes.

  • Industry Explorers: Leading Business With Science — Part 2
    Industry Explorers: Leading Business With Science — Part 2

    We continue the story of Geert Cauwenbergh whose nearly 40 years in the industry included work with Paul Janssen as well as being a startup entrepreneur with RXi Pharmaceuticals.

More From Wayne Koberstein
Wayne Koberstein

Wayne Koberstein


Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.